(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Shades Brands For Seniors - 2Taylor Swift just released the 'Elizabeth Taylor' music video — but she's not the star of it
- 3Tech giants accused of not complying with Australian social media ban
- 44K televisions for Extreme Film Watching Experience
- 5What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Polar bears are rewiring their own genetics to survive a warming climate
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972
- Compassion and Association: Building Significant Connections
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
- The cheap health insurance promoted by Trump officials has this catch
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- Grasping the Basics of Business Land Regulation
